Tag Archives: Randox Toxicology

December 2013—Randox’s two new controls, Acusera Liquid Assayed Chemistry Premium and Premium Plus, are designed to drastically cut the number of individual quality controls a laboratory needs to run in routine medical testing while providing clinically significant values for a wide range of analyzers at key decision points.

Randox Laboratories has received FDA approval for its Acusera immunoassay specialty 1 control for use in U.S. laboratories. The multi-analyte, lyophilized control contains I-25-(OH)2-vitamin D, 25-OH-vitamin D, C peptide, insulin, insulin-like growth factor-1, procalcitonin, parathyroid hormone, anti-thyroglobulin, and anti-thyroperoxidase.

Randox Toxicology has developed an ELISA that targets UR-144, XLR-11, and additional synthetic cannabinoid compounds, which are commonly found in new “Spice” and “K2” blends. Together with the company’s JWH/AM2201 synthetic cannabinoids ELISA, the UR-144/XLR-11 ELISA provides a comprehensive solution for the rapid detection of more than 55 current synthetic cannabinoids in urine, blood, and oral fluid.

Randox Toxicology offers three new ELISA testing kits for the detection of sedative drugs zopiclone, zaleplon, and zolpidem, which behave similarly to benzodiazepines. Randox developed the ELISA kits for the detection of these drugs in urine and blood specimens. The zolpidem ELISA offers a limit of detection of 0.4 ng/mL in urine and 0.52 ng/mL in blood.